



Association of British Neurologists

Programme of the Annual Meeting

21-23 May 2019 (Tues - Thurs)

EICC Edinburgh

Tuesday 21 May			
07:45	Committee meetings		
09:00	Opening and Welcome		
09:15	Plenary session 1: Cells and Cellular Therapies: from bench to bedside Chair: Martin Turner, Don Mahad <ul style="list-style-type: none"> • iPS stem cells as models of disease: Siddhartan Chandran, Edinburgh • Bone marrow - a real prospect: Martin Duddy, Newcastle • Neurology of CAR-T therapies: Claire Roddie, London 		
10:45	Coffee, Exhibition & Silent Symposium: Pharnext: CMT Natural History – The reality of living with CMT		
11:15	<table border="0" style="width: 100%;"> <tr> <td style="width: 50%; padding: 5px;">Parallel session 1: Clinical Neurology (1) Chair: David Nicholl, Jennifer Quirk</td> <td style="width: 50%; padding: 5px;">Parallel session 2: Quality Chair: Christopher Kipps, Arani Nitkunan</td> </tr> </table>	Parallel session 1: Clinical Neurology (1) Chair: David Nicholl, Jennifer Quirk	Parallel session 2: Quality Chair: Christopher Kipps, Arani Nitkunan
Parallel session 1: Clinical Neurology (1) Chair: David Nicholl, Jennifer Quirk	Parallel session 2: Quality Chair: Christopher Kipps, Arani Nitkunan		
Lunch, Exhibition			
12:30	<table border="0" style="width: 100%;"> <tr> <td style="width: 50%; padding: 5px;">Teva Symposium: Anti-CGRP biologics for migraine prevention: How do they work and what is the clinical evidence?</td> <td style="width: 50%; padding: 5px;">Janssen Symposium: Combining DMTs: A potential way forward for RMS</td> </tr> </table>	Teva Symposium: Anti-CGRP biologics for migraine prevention: How do they work and what is the clinical evidence?	Janssen Symposium: Combining DMTs: A potential way forward for RMS
Teva Symposium: Anti-CGRP biologics for migraine prevention: How do they work and what is the clinical evidence?	Janssen Symposium: Combining DMTs: A potential way forward for RMS		
14:00	Gordon Holmes lecture Introduction: Michael Hanna Charles Thornton, Rochester New York Prospects for developing treatment for myotonic dystrophy		
14:45	<table border="0" style="width: 100%;"> <tr> <td style="width: 50%; padding: 5px;">Parallel session 3: Phenotype and Genotypes Chair: Kevin Talbot, John Ealing</td> <td style="width: 50%; padding: 5px;">Parallel session 4: Treatments; looking to the future Chair: Lucy Kinton, Raeburn Forbes</td> </tr> </table>	Parallel session 3: Phenotype and Genotypes Chair: Kevin Talbot, John Ealing	Parallel session 4: Treatments; looking to the future Chair: Lucy Kinton, Raeburn Forbes
Parallel session 3: Phenotype and Genotypes Chair: Kevin Talbot, John Ealing	Parallel session 4: Treatments; looking to the future Chair: Lucy Kinton, Raeburn Forbes		
16.00	Coffee, Exhibition & Silent Symposium: Pharnext: CMT Natural History – The reality of living with CMT		
16:30	Plenary session 2: Epilepsy Chair: Lina Nashef, Meneka Sidhu <ul style="list-style-type: none"> • Gene therapy and epilepsy SUDEP Mechanisms : Matthew Walker, London • Drugs and epilepsy: New and old: John Paul Leach, Glasgow • Epilepsy: How far do you go?: Anthony Marson, Liverpool 		
18.00	Poster session with discussants 1		
19.00	Drinks reception + posters + research opportunities forum		

Wednesday 22 May

Wednesday 22 May			
07:45	Functional disorders SIG 1	Myasthenia Gravis SIG 2	Neuro-oncology SIG 3
09:00	Plenary session 3: Movement disorders Chair: Donald Grosset, Sharon Muzerengi <ul style="list-style-type: none"> When the honeymoon's over: new drugs in PD: Carl Clarke, Birmingham Sleep and neurodegeneration: Paul Reading, Middlesbrough Dystonia: Tom Warner, London 		
10:30	Coffee, Exhibition and Silent Symposium: Santhera: Patients with vision loss - when to look beyond MS		
11:00	Poster session with discussants 2		
12:00	ABN Medallist lecture: Pamela Shaw, Sheffield Citation: Chris McDermott Chair: Mary Reilly Translational neuroscience to improve outcomes for motor neurone disease: the blessings and challenges of the journey		
12.45	Lunch, Exhibition		
12.45	Novartis Symposium: A new era of migraine management: Real world experience: Erenumab	Merck Symposium: The current UK Multiple Sclerosis (MS) service capacity challenge: What's the scale of the issue?	
14:15	AGM + Committee reports		
15:45	Coffee, Exhibition and Silent Symposium: Santhera: Patients with vision loss - when to look beyond MS		
16.15	Plenary session 4: Modern dilemmas: 'Assisted Dying' Chair: David Burn, Newcastle <ul style="list-style-type: none"> Jacqueline Palace, Oxford Uma Nath, Sunderland 		
17:15	President's lecture: David Burn, Newcastle Walking the wheel the wrong way		
18:00			
19:00	Gala Dinner: The Stables, Prestonfields		

Thursday 23 May

07.30	Fun Run (not in final handbook)		
07:45	Motor Neurone Disease SIG 4	Multiple Sclerosis & Neuroinflammation SIG 5	Headache SIG 6
09:00	Case presentation competition Chair: Phillip Smith		
10:15	Practical Neurology lecture Chair: Geraint Fuller, Phillip Smith Robin Ferner, Birmingham Harm from medicines		
11:00	Coffee, Exhibition and Silent Symposium: AveXis		
11:30	Parallel session 5: Neurological treatment Chair: Trevor Pickersgill, Fiona McKeivitt	Parallel session 6: Clinical neurology (2) Chair: Jacqueline Palace, Christopher Kobylecki	
12.45	Lunch, Exhibition		Novartis MS Symposium: Managing states of MS disease transition - the child to adult, and relapsing to secondary progressive MS
			Biogen Symposium: (SMA) an overview on therapeutic advances in Spinal Muscular Atrophy.
14:15	Plenary session 5: Pause for thought... What should I do now? Chair: Cath Mummery, Claire Gall <ul style="list-style-type: none"> • Dilemmas and the spinal cord : Geraint Fuller, Gloucester • Neurology in the tropics - A Sri Lankan experience: Thashi Chang, President ASN • Thunderclap headache: Can I send this patient home?: Nicola Giffin, Bath 		
15:15	CPC Discussant: Ed Newman Chair: Jon Sussman		
16:00	Top 5 posters Chair: Tom Warner		
16.45	Prize presentations and close Chair: David Burn		
17:00			